Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Outlook Therapeutics stock in Canada | $2.68
Own Outlook Therapeutics shares in just a few minutes.
Outlook Therapeutics is a biotechnology business based in the US. Outlook Therapeutics stocks (OTLK.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.5 – an increase of 8.06% over the previous week. Outlook Therapeutics employs 8 staff and has a trailing 12-month revenue of around $5.9 million.
How to buy Outlook Therapeutics stock in Canada
- Choose a platform. If you're a beginner, our stock trading table below can help you choose.
- Open your account. You'll need your ID, bank details and national insurance number.
- Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
- Search the platform for stock code: OTLK in this case.
- Research Outlook Therapeutics stocks. The platform should provide the latest information available.
- Buy your Outlook Therapeutics stocks. It's that simple.
What's in this guide?
- Can I buy shares in Outlook Therapeutics?
- Has coronavirus impacted Outlook Therapeutics shares?
- Outlook Therapeutics shares summary
- Compare share dealing platforms
- Is Outlook Therapeutics stock a buy or sell?
- Outlook Therapeutics performance over time
- Can I short Outlook Therapeutics shares?
- Outlook Therapeutics's financials
- How volatile are Outlook Therapeutics shares?
- Does Outlook Therapeutics pay a dividend?
- Have Outlook Therapeutics shares ever split?
- Other common questions
How has Coronavirus impacted Outlook Therapeutics's stock price?
Since the stock market crash in March caused by coronavirus, Outlook Therapeutics's stock price has had significant positive movement.
Its last market close was $2.68, which is 64.43% up on its pre-crash value of $0.9534 and 437.07% up on the lowest point reached during the March crash when the stocks fell as low as $0.499.
If you had bought $1,000 worth of Outlook Therapeutics stocks at the start of February 2020, those stocks would have been worth $582.38 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $2,865.40.
Outlook Therapeutics stock priceUse our graph to track the performance of OTLK stocks over time.
Outlook Therapeutics stocks at a glance
|Latest market close||$2.68|
|52-week range||$0.58 - $4.26|
|50-day moving average||$2.4935|
|200-day moving average||$2.153|
|Wall St. target price||$5.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.886|
Compare online stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
Is it a good time to buy Outlook Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Outlook Therapeutics price performance over time
|1 month (2021-06-25)||10.74%|
|3 months (2021-04-26)||18.06%|
Outlook Therapeutics financials
|Revenue TTM||USD$5.9 million|
|Gross profit TTM||USD$-26,341,998|
|Return on assets TTM||-104.25%|
|Return on equity TTM||-64034.97%|
|Market capitalisation||USD$430.5 million|
TTM: trailing 12 months
How to short and sell Outlook Therapeutics stocks
- Create a CFD or spread betting account.
- Search for the stock code. E.g. "OTLK.US"
- Choose your position size.
- Select "sell" rather than "buy".
- Confirm your position and keep tabs on it. You may wish to set limits on your position.
There are currently 4.2 million Outlook Therapeutics stocks held short by investors – that's known as Outlook Therapeutics's "short interest". This figure is 214.1% up from 1.3 million last month.
There are a few different ways that this level of interest in shorting Outlook Therapeutics stocks can be evaluated.
Outlook Therapeutics's "short interest ratio" (SIR)
Outlook Therapeutics's "short interest ratio" (SIR) is the quantity of Outlook Therapeutics stocks currently shorted divided by the average quantity of Outlook Therapeutics stocks traded daily (recently around 1.3 million). Outlook Therapeutics's SIR currently stands at 3.37. In other words for every 100,000 Outlook Therapeutics stocks traded daily on the market, roughly 3370 stocks are currently held short.
However Outlook Therapeutics's short interest can also be evaluated against the total number of Outlook Therapeutics stocks, or, against the total number of tradable Outlook Therapeutics stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Outlook Therapeutics's short interest could be expressed as 0.02% of the outstanding stocks (for every 100,000 Outlook Therapeutics stocks in existence, roughly 20 stocks are currently held short) or 0.0475% of the tradable stocks (for every 100,000 tradable Outlook Therapeutics stocks, roughly 48 stocks are currently held short).
Such a low SIR usually points to an optimistic outlook for the stock price, with fewer people currently willing to bet against Outlook Therapeutics.
Find out more about how you can short Outlook Therapeutics stock.
Outlook Therapeutics stock dividends
We're not expecting Outlook Therapeutics to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.
Have Outlook Therapeutics stocks ever split?
Outlook Therapeutics stocks were split on a 1:8 basis on 18 March 2019. So if you had owned 8 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Outlook Therapeutics stocks – just the quantity. However, indirectly, the new 700% higher stock price could have impacted the market appetite for Outlook Therapeutics stocks which in turn could have impacted Outlook Therapeutics's stock price.
Outlook Therapeutics stock price volatility
Over the last 12 months, Outlook Therapeutics's stocks have ranged in value from as little as $0.58 up to $4.26. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Outlook Therapeutics's is 0.6817. This would suggest that Outlook Therapeutics's stocks are less volatile than average (for this exchange).
Outlook Therapeutics overview
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cranbury, New Jersey.
Stocks similar to Outlook Therapeutics
Outlook Therapeutics in the news
When Will Outlook Therapeutics, Inc. (NASDAQ:OTLK) Turn A Profit?
Outlook Therapeutics Appoints C. Russell Trenary III as President and Chief Executive Officer
Outlook Therapeutics Names Trenary as President, CEO >OTLK
Frequently asked questions
More guides on Finder
How to buy Ryan Specialty Group Holdings (RYAN) stock in Canada
Everything we know about the Ryan Specialty Group Holdings IPO, plus information on how to buy in.
How to buy Ocean Biomedical (OCEA) stock in Canada when it goes public
Everything we know about the Ocean Biomedical IPO, plus information on how to buy in.
How to buy Instructure Holdings (INST) stock in Canada
Everything we know about the Instructure Holdings IPO, plus information on how to buy in.
How to buy Gambling.com Group (GAMB) stock in Canada
Everything we know about the Gambling.com Group IPO, plus information on how to buy in.
How to buy Elicio Therapeutics (ELTX) stock in Canada when it goes public
Everything we know about the Elicio Therapeutics IPO, plus information on how to buy in.
How to buy Cytek Biosciences (CTKB) stock in Canada
Everything we know about the Cytek Biosciences IPO, plus information on how to buy in.
How to buy Core & Main (CNM) stock in Canada
Everything we know about the Core & Main IPO, plus information on how to buy in.
How to buy Caribou Bioscience (CRBU) stock in Canada
Everything we know about the Caribou Bioscience IPO, plus information on how to buy in.
How to buy Candel Therapeutics (CADL) stock in Canada when it goes public
Everything we know about the Candel Therapeutics IPO, plus information on how to buy in.
How to buy Absci Corporation (ABSI) stock in Canada
Everything we know about the Absci Corporation IPO, plus information on how to buy in.
Ask an Expert
You must be logged in to post a comment.